{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kim HP"],"funding":["NIDDK NIH HHS","NCRR NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases"],"pagination":["2199-2201"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8007645"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(10)"],"pubmed_abstract":["Oxaliplatin is an alkylating agent given with fluorouracil and leucovorin as a mainstay adjuvant chemotherapy for stage III colorectal cancer (CRC). Liver injury from oxaliplatin ranges from mild liver enzyme increases in 42% to 57% of patients in clinical trials<sup>1</sup> to rare severe injury leading to acute liver failure.<sup>2</sup> Chronic injury from endothelial cell damage and architectural distortion may manifest years later with nodular regenerative hyperplasia (NRH), portal sclerosis, and noncirrhotic portal hypertension (NCPH).<sup>2</sup><sup>,</sup><sup>3</sup> Chronic subclinical injury occurs in up to 78% of patients.<sup>3</sup> Diagnosis may be confounded by nonalcoholic fatty liver disease (NAFLD), and long-term outcomes from chronic injury are unclear."],"journal":["Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"],"pubmed_title":["The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease."],"pmcid":["PMC8007645"],"funding_grant_id":["U01 DK065201","U01 DK065211","U01 DK065176","U01 DK083023","U01 DK083020","U01 DK083027","U01 DK100928","U01 DK082992","U24 DK065176","U01 DK065238","UL1 RR025747","UL1 RR024986","U01 DK065184","UL1 RR024134","UL1 RR024982","U01 DK065193","UL1 RR025761","T32 DK007634","UL1 RR024150"],"pubmed_authors":["Hayashi PH","Odin J","Navarro V","Zacks S","Kleiner DE","Kim HP","Drug-Induced Liver Injury Network Investigators"],"additional_accession":[]},"is_claimable":false,"name":"The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease.","description":"Oxaliplatin is an alkylating agent given with fluorouracil and leucovorin as a mainstay adjuvant chemotherapy for stage III colorectal cancer (CRC). Liver injury from oxaliplatin ranges from mild liver enzyme increases in 42% to 57% of patients in clinical trials<sup>1</sup> to rare severe injury leading to acute liver failure.<sup>2</sup> Chronic injury from endothelial cell damage and architectural distortion may manifest years later with nodular regenerative hyperplasia (NRH), portal sclerosis, and noncirrhotic portal hypertension (NCPH).<sup>2</sup><sup>,</sup><sup>3</sup> Chronic subclinical injury occurs in up to 78% of patients.<sup>3</sup> Diagnosis may be confounded by nonalcoholic fatty liver disease (NAFLD), and long-term outcomes from chronic injury are unclear.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2025-04-03T22:35:42.757Z","creation":"2024-10-16T04:30:41.231Z"},"accession":"S-EPMC8007645","cross_references":{"pubmed":["33007507"],"doi":["10.1016/j.cgh.2020.09.038"]}}